Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | RET | P07949 | 8/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15539980 | 0.90 | GPR119 (0.34) | CYP3A4GPR119RETMAPT | |
| SCHEMBL21639716 | 0.87 | CYP3A4 (0.37) | CYP3A4GPR119RETMAPTPPIA | |
| SCHEMBL1282700 | 0.87 | CYP3A4 (0.37) | CYP3A4GPR119RETMAPTPPIA | |
| SCHEMBL28719905 | 0.86 | RET (0.42) | RET | |
| SCHEMBL20137774 | 0.85 | RET (0.43) | CYP3A4GPR119RETMAPT | |
| SCHEMBL15416347 | 0.83 | CYP3A4 (0.40) | CYP3A4GPR119RETPPIA | |
| SCHEMBL15415397 | 0.78 | CYP3A4 (0.42) | CYP3A4MAPT | |
| SCHEMBL15415493 | 0.78 | CYP3A4 (0.42) | CYP3A4RETMAPT | |
| SCHEMBL16909548 | 0.77 | CYP3A4 (0.44) | CYP3A4MAPT | |
| SCHEMBL1282440 | 0.76 | PANK3 (0.39) | CYP3A4GPR119RETMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | CYP3A4 1261/4885GPR119 498/4885RET 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.